OrbiMed Portfolio holdings
OrbiMed is an investment manager focused exclusively on healthcare, running public equity, private equity and private credit and royalty funds. The firm traces its origins to 1989, when Viren Mehta and Samuel Isaly, both pharmaceutical analysts at the bank S.G Warburg, set up the research and money-management firm Mehta & Isaly; in 1998 it split in two, with Isaly forming OrbiMed and Mehta forming Mehta Partners. Its public equity side covers long/short funds built around corporate events as well as closed-end investment trusts, and OrbiMed launched its first dedicated venture capital fund in 2000 and its first royalty and credit fund in 2011. Carl Gordon, Carter Neild and Geoffrey Hsu form the committee that leads the firm, which is owned and controlled by eight members.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SVA
Sinovac Biotech, Ltd
SVA
|
+$349M |
| 2 |
Progyny
PGNY
|
+$22.4M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$19.5M |
| 4 |
Travere Therapeutics
TVTX
|
+$19.4M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$17.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$76.7M |
| 2 |
Pfizer
PFE
|
+$59.2M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$50.3M |
| 4 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$40.2M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$34.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.72% |
| 2 | Miscellaneous | 2.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $350M | 6.33% |
+2,718,735
| New | +$349M |
2022 Q2
0 quarters
|
|
2
Bristol-Myers Squibb
BMY
$128B
| $194M | 3.51% |
2,518,700
-89,000
| -3% | -$6.78M |
2019 Q4
10 quarters
|
|
3
Humana
HUM
$49.8B
| $171M | 3.1% |
365,700
-16,000
| -4% | -$7.12M |
2019 Q3
11 quarters
|
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $168M | 3.05% |
2,108,555
-88,000
| -4% | -$8.33M |
2019 Q4
10 quarters
|
|
5
Boston Scientific
BSX
$60.8B
| $163M | 2.95% |
4,369,500
-230,000
| -5% | -$9.36M |
2014 Q1
33 quarters
|
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $151M | 2.74% |
2,012,250
-6,700
| -0.3% | -$298K |
2019 Q2
12 quarters
|
|
7
DELISTED
SpringWorks Therapeutics
SWTX
| $148M | 2.69% |
6,028,307
| – | – |
2019 Q3
11 quarters
|
|
8
UnitedHealth
UNH
$365B
| $144M | 2.62% |
281,200
-13,000
| -4% | -$6.53M |
2020 Q4
6 quarters
|
|
|
9
Pfizer
PFE
$174B
| $144M | 2.61% |
2,744,000
-1,161,500
| -30% | -$59.2M |
2021 Q4
2 quarters
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.3B
| $141M | 2.55% |
1,699,710
+52,680
| +3% | +$4.19M |
2021 Q3
3 quarters
|
|
11
AbbVie
ABBV
$521B
| $122M | 2.22% |
799,800
-115,800
| -13% | -$17.7M |
2020 Q1
9 quarters
|
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $122M | 2.2% |
687,500
+19,800
| +3% | +$2.85M |
2021 Q3
3 quarters
|
|
13
Edgewise Therapeutics
EWTX
$4.22B
| $112M | 2.03% |
14,082,680
+138,000
| +1% | +$1.04M |
2021 Q1
5 quarters
|
|
14
Vertex Pharmaceuticals
VRTX
$142B
| $109M | 1.98% |
387,200
-13,000
| -3% | -$3.48M |
2013 Q2
36 quarters
|
|
15
Adicet Bio
ACET
$32M
| $109M | 1.97% |
465,446
| – | – |
2018 Q1
17 quarters
|
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $108M | 1.96% |
1,964,770
| – | – |
2020 Q1
9 quarters
|
|
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $105M | 1.9% |
719,034
| – | – |
2022 Q1
1 quarter
|
|
18
Intuitive Surgical
ISRG
$153B
| $104M | 1.88% |
517,200
-17,000
| -3% | -$3.99M |
2013 Q4
34 quarters
|
|
19
Arcutis Biotherapeutics
ARQT
$4.03B
| $102M | 1.85% |
4,781,646
-1,292,204
| -21% | -$26.5M |
2020 Q1
9 quarters
|
|
|
TCDA
20
DELISTED
Tricida, Inc. Common Stock
TCDA
| $100M | 1.8% |
10,280,947
| – | – |
2018 Q2
16 quarters
|
|
21
Edwards Lifesciences
EW
$53B
| $96.2M | 1.74% |
1,011,300
-40,000
| -4% | -$4.14M |
2016 Q1
25 quarters
|
|
|
THRX
22
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $94.2M | 1.71% |
17,041,668
| – | – |
2021 Q4
2 quarters
|
|
23
PMV Pharmaceuticals
PMVP
$70M
| $93.5M | 1.69% |
6,563,077
-292,346
| -4% | -$4.25M |
2020 Q3
7 quarters
|
|
24
Stryker
SYK
$112B
| $87.7M | 1.59% |
441,100
-16,000
| -4% | -$3.76M |
2020 Q3
7 quarters
|
|
25
Neurocrine Biosciences
NBIX
$14.9B
| $82.8M | 1.5% |
849,545
-25,970
| -3% | -$2.4M |
2018 Q1
17 quarters
|
|
Similar funds
OrbiMed's Q2 2022 Portfolio in Review
As of Q2 2022, OrbiMed held 158 positions worth $5.52B, down 11% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
OrbiMed's Q2 2022 filing shows 15 new, 26 increased, 36 reduced and 15 closed positions. Its largest new stake was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M. The largest sale was DexCom, an estimated $76.7M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.
- OrbiMed's largest Q2 2022 buy was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M.
- OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
- OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
- OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
- OrbiMed's ten largest holdings make up 32% of its $5.52B portfolio in Q2 2022.
- OrbiMed opened 15 new positions and closed 15 in Q2 2022.
- OrbiMed's portfolio value fell 11% quarter-over-quarter to $5.52B.
Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.